1. Home /
    2. Altai Protocol Library /
  2. New Drug: Infigratinib for FGFR2+ cholangiocarcinoma

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Drug: Infigratinib for FGFR2+ cholangiocarcinoma

New Drug: Infigratinib for FGFR2+ cholangiocarcinoma
Study:
  • Single-arm phase II study (BGJ398)
  • Advanced/metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements with progression on >= 1 line
  • Infigratinib 125 mg PO daily (21/28 days)
Efficacy:
  • ORR: 23.1% [15.6%-32.2%]
  • Median DoR: 5.0 mos (range 0.9 – 19.1 mos)
  • Median PFS: 7.3 mos [5.6-7.6 mos]
Safety:
  • Grade >=3 AEs: Stomatitis (15%), hyponatremia (13%), hypophosphatemia (13%), central serous retinopathy (1%)

J Clin Oncol 2021;39(3):suppl 265-265

Javle MM, et al. Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement

https://doi.org/10.1200/JCO.2021.39.3_suppl.265

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More